A study published in Nature magazine analysed the medical records of elderly Welsh men and women and discovered that those who had been vaccinated against shingles were 20% less likely to develop dementia in the following seven years. This effect was greater in women. The findings support the theory that viruses that affect the nervous system can increase the risk of dementia.
EMA’s human medicines committee has recommended not authorising the marketing of Kisunla (donanemab), a drug intended for the treatment of early-stage Alzheimer's disease. The committee considered that the benefits of this drug were not great enough to outweigh the risk of potentially fatal events. In recent years, several patients have died due to microbleeds in the brain.
The DIAN-TU platform is an initiative to test Alzheimer's disease treatments early, by recruiting people with a mutation that leads to developing the disease in the future. One of the trials with the anti-amyloid drug gantenerumab ended without reaching the targets. However, a continuation of the study in 73 patients suggests - for the first time, according to the authors - that long-term, high-dose treatment given some time before symptoms develop could delay the onset of the disease. The results are published in the journal The Lancet Neurology.
Discovered years ago, PINK1 is a protein directly linked to Parkinson's disease, but it was not known what it looks like, how it binds to the surface of damaged mitochondria or how it is activated. A study published this week in Science has for the first time determined the structure of this protein. The authors suggest that this new information could help in finding new treatments.
Epstein-Barr virus infection appears to be a necessary condition for developing multiple sclerosis, but the specific mechanisms that cause it in some people are not known. An international study of more than 1,300 people, including 650 patients, has found that elevated production of certain antibodies increases the risk of developing the disease. These antibodies target a specific protein in the virus, but can in turn act in a cross-species manner and damage other similar proteins in the nervous system. The results are published in the journal PNAS.
In 2050 there will be 25.2 million people with Parkinson's disease worldwide, which represents an increase of 112% from 2021, largely due to the ageing of the population, according to a modelling study published by The BMJ. The number of people living with this disease – prevalence across all ages – per 100,000 inhabitants is expected to increase by 76% – and by 55% when age differences are corrected.
A study led by researchers in Canada has analysed the relationship between perimenopausal symptoms and later cognitive and behavioural problems in nearly 900 women. Their findings are that those with more symptoms were more at risk of cognitive problems and dementia later in life. The results are published in the journal Plos One.
A team from the University of Iowa (USA) has found a relationship between specific species of microbiota bacteria and the severity of multiple sclerosis. Specifically, a lower ratio between the quantities of Bifidobacterium and Akkermansia was related to the disease and to a worse course of the disease, both in mice and in two cohorts of patients and people without the disease. According to the authors, who publish the results in the journal PNAS, the finding could be used to improve the diagnosis and treatment of multiple sclerosis.
People with dementia who are prescribed a specific type of antidepressant experience a faster cognitive decline than people who do not use these drugs, according to a study published in BMC Medicine. In particular, prescriptions for higher doses of selective serotonin reuptake inhibitors (SSRIs), a type of antidepressant, were associated with a higher risk of severe dementia, fractures and mortality. The analysis includes data from more than 18,000 patients from a Swedish database between 2007 and 2018.
A study by Italian researchers has tested a treatment administered as a nasal spray to slow down early-stage Alzheimer's disease. Administered in mice, the treatment inhibits an enzyme linked to the disease and to insulin resistance. According to the researchers, who publish the work in the journal PNAS, application of the spray to the animals “can counteract the accumulation of harmful proteins in neurons and delay the onset and progression of cognitive decline”.